中药FYTF-919(中风醒脑口服方)治疗急性脑出血:多中心、随机、安慰剂对照、双盲临床试验
该研究在中国26家医院开展随机双盲安慰剂对照试验,纳入1648例中重度急性自发性脑出血患者,比较FYTF-919口服液与安慰剂。90天效用加权改良Rankin量表评分两组均为0.44(差值0.01,95%CI -0.02至0.04;p=0.63),严重不良事件无显著差异。结论认为FYTF-919对功能恢复、生存和健康相关生活质量无效果。
要点
- 中重度急性脑出血患者90天效用加权mRS评分FYTF-919组0.44 vs 安慰剂组0.44,差值0.01(95%CI -0.02至0.04;p=0.63)。
- FYTF-919组与安慰剂组严重不良事件无显著差异。
- 调整分析和敏感性分析结果一致,均显示中性结果。
核心结论
- 该大型随机双盲安慰剂对照试验显示,中药复方FYTF-919对中重度脑出血患者的功能恢复、生存和健康相关生活质量无效果。
研究设计与样本
- 实用性、多中心、随机、双盲、安慰剂对照试验,在中国26家医院开展。
- 纳入年龄≥18岁、症状发作(或最后确认正常)48小时内经脑影像确诊的症状性自发性脑出血患者,神经功能缺损为中重度(NIHSS评分至少8分或GCS评分7至14分)。
- 采用中央互联网系统按1:1随机分组,区组分层因素为医院所在省份、神经功能缺损严重程度和脑内血肿部位。
- FYTF-919组817例、安慰剂组831例;随机后未接受治疗即退出知情同意者FYTF-919组2例、安慰剂组5例,意向性治疗人群有主要结局数据者1641例(FYTF-919组815例、安慰剂组826例)。
- 干预为每日口服FYTF-919或匹配安慰剂33 mL(吞咽障碍者经鼻胃管25 mL),餐后至少30分钟给药,每8小时一次(经鼻胃管每6小时一次),持续28天。
主要发现
- 90天效用加权改良Rankin量表平均评分FYTF-919组0.44 vs 安慰剂组0.44(差值0.01,95%CI -0.02至0.04;p=0.63)。
- 调整分析和敏感性分析中中性结果一致。
- 严重不良事件无显著差异。
- 1242例(75.7%)在28天内服用研究药物达到80%或以上,994例(60.6%)服用全部药物。
关键数值与推荐
- 主要疗效结局为90天效用加权改良Rankin量表评分,该量表为七级有序量表(0分无症状至6分死亡),七级对应效用权重分别为0.97、0.88、0.74、0.55、0.20、-0.19和0.00,评分越高表示结局越好。
- 主要分析在意向性治疗人群中进行,采用一般线性模型并校正基线因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are few proven treatments for acute spontaneous intracerebral haemorrhage, and they all target reducing expansion of the haematoma. The traditional Chinese medicine FYTF-919 (Zhongfeng Xingnao) in an oral solution is comprised of several Chinese herbs that are widely used to treat patients with intracerebral haemorrhage in China on the understanding that they enhance resorption of the haematoma and reduce neuroinflammation. We aimed to provide a reliable assessment of the safety and efficacy of FYTF-919 in patients with moderate to severe acute intracerebral haemorrhage. METHODS: We did a pragmatic, multicentre, randomised, double-blind, placebo-controlled trial at 26 hospitals in China. We enrolled adults (age ≥18 years) with a diagnosis of symptomatic spontaneous intracerebral haemorrhage (confirmed by brain imaging) within 48 h after the onset of symptoms (or last seen well), which resulted in moderate to severe neurological impairment defined by scores of at least 8 on the National Institute of Health Stroke Scale or between 7 and 14 inclusive on the Glasgow Coma Scale. Randomisation (1:1) was via a central internet-based system with a block grouping method stratified by provincial location of the hospital, severity of neurological impairment, and site of the haematoma in the brain. FYTF-919 and the placebo were masked through consistency in appearance, smell, taste, and other aspects. Participants were allocated to receive 33 mL (or 25 mL via a nasogastric tube if a participant's swallowing was impaired) of either oral liquid FYTF-919 or matching placebo administered at least 30 min after a meal every 8 h (or 6 h via nasogastric tube) over 24 h for 28 days. The primary efficacy outcome was the utility weighted modified Rankin Scale (a seven-level ordinal scale that ranges from 0 [no symptoms] to 6 [death], in which the utility weights of 0·97, 0·88, 0·74, 0·55, 0·20, -0·19, and 0·00 were assigned to the seven levels respectively, with higher scores indicating a better outcome according to the participants' perspective) at 90 days analysed in a general linear model with adjustment for baseline factors. We did several adjusted and sensitivity analyses. Primary analyses were assessed in the intention-to-treat population. This trial is registered at ClinicalTrials.gov, NCT05066620 and is complete. FINDINGS: Between Nov 24, 2021, and Dec 28, 2023, of 9000 patients screened, 1648 were randomly assigned to treatment, 817 to the FYTF-919 group and 831 to the placebo group. Before receiving any treatment two patients in the FYTF-919 group and five patients in the placebo group immediately withdrew their consent leaving 1641 participants with available primary outcome data in the intention-to-treat population, 815 in the FYTF-919 group and 826 in the placebo group. 1242 (75·7%) participants consumed 80% or more of the study medication and 994 (60·6%) consumed all of it within 28 days. Mean utility weighted modified Rankin Scale scores at 90 days were 0·44 in the FYTF-919 group and 0·44 in the placebo group (difference 0·01, 95% CI -0·02 to 0·04; p=0·63). The neutral result was consistent in adjusted and sensitivity analyses. There was no significant difference in serious adverse events. INTERPRETATION: This large, randomised, placebo-controlled, double-blind, clinical trial showed no effect of the traditional Chinese medicine herbal compound FYTF-919 on functional recovery, survival, and health-related quality of life in patients with moderate to severe intracerebral haemorrhage. The results reaffirm the need for methodologically rigorous, randomised controlled trials to evaluate the effectiveness of existing therapies, including traditional Chinese medicines that are already in widespread use throughout the world. FUNDING: Key-Area Research and Development Program of Guangdong Province.
引用
- Guo J, Chen X, Wu M, et al. Traditional Chinese medicine FYTF-919 (Zhongfeng Xingnao oral prescription) for the treatment of acute intracerebral haemorrhage: a multicentre, randomised, placebo-controlled, double-blind, clinical trial. Lancet. 2024. PMID: 39547249. doi:10.1016/S0140-6736(24)02261-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。